Bringing the Oncology Community Together
PREVAIL Trial Investigator Discusses Pre-Chemo Enzalutamide Indication
Last week, the FDA expanded the approval for enzalutamide (Xtandi) to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.
Read More >>
Robotic Prostatectomy Rises, and So Do Costs: Study Tracks Patterns
Vessel-Sparing Radiation Preserves Sexual Function in Men With Prostate Cancer
Abbreviated Course of ADT + Radiation Improves QoL in High-Risk Prostate Cancer
Beyond PSA: A Summary Review of Predictive/Prognostic Biomarkers in Prostate Cancer
FDA Approves Pre-Chemo Enzalutamide for mCRPC
UCSF Researcher Puts Focus on AR Resistance Mechanisms
View More >>
- A Network of Your Peers
View more >>
Treating Symptomatic Bone Metastatic CRPC
Dr. Hussain on the Importance of Multidisciplinary Care
Multidisciplinary Approach to mCRPC Treatment
Most Popular Right Now
Tweets by @OncLive
Genomic Testing for Newly Diagnosed Low-Risk Prostate Cancer
E. David Crawford, MD, Steven E. Canfield, MD, Marc A. Dall'Era, MD, and Neal Shore, MD, discuss genomic testing for newly diagnosed, low-risk prostate cancer.
Updates in the Management of CRPC
Moderated by Raoul S. Concepcion, MD, this panel discussion includes expert perspectives from Neal D. Shore, MD, Paul R. Sieber, MD, E. David Crawford, MD, and Mark S. Austenfeld, MD.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.